Sarepta Therapeutics Inc SRPT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/27/23 EST
122.89UNCH (UNCH)
Volume
12,039
Close
122.89quote price arrow down-1.58 (-1.27%)
Volume
712,001
52 week range
61.28 - 134.08
Loading...
  • Open124.53
  • Day High126.11
  • Day Low121.89
  • Prev Close124.47
  • 52 Week High134.08
  • 52 Week High Date12/22/22
  • 52 Week Low61.28
  • 52 Week Low Date06/16/22

Key Stats

  • Market Cap10.788B
  • Shares Out87.78M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.98
  • YTD % Change-5.16

KEY STATS

  • Open124.53
  • Day High126.11
  • Day Low121.89
  • Prev Close124.47
  • 52 Week High134.08
  • 52 Week High Date12/22/22
  • 52 Week Low61.28
  • 52 Week Low Date06/16/22
  • Market Cap10.788B
  • Shares Out87.78M
  • 10 Day Average Volume1.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.98
  • YTD % Change-5.16

RATIOS/PROFITABILITY

  • EPS (TTM)-8.21
  • P/E (TTM)-14.97
  • Fwd P/E (NTM)-20.74
  • EBITDA (TTM)-493.725M
  • ROE (TTM)-159.10%
  • Revenue (TTM)876.047M
  • Gross Margin (TTM)83.91%
  • Net Margin (TTM)-81.76%
  • Debt To Equity (MRQ)358.08%

EVENTS

  • Earnings Date02/27/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Sarepta Therapeutics Inc

 

Profile

MORE
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (Duchenne), Limb-girdle muscular dystrophies (LGMDs) and other...
M. Kathleen Behrens Ph.D.
Independent Chairwoman of the Board
Douglas Ingram Esq., J.D.
President, Chief Executive Officer, Director
Ian Estepan
Chief Financial Officer, Executive Vice President
Louise Rodino-Klapac Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R and D
Address
215 1st St Ste 415
Cambridge, MA
02142-1213
United States

Top Peers

SYMBOLLASTCHG%CHG
NVZMY
Novozymes A/S
50.71-0.18-0.35%
NBIX
Neurocrine Biosciences Inc
108.25-0.13-0.12%
NVCR
Novocure Ltd
90.90+0.85+0.94%
EXAS
Exact Sciences Corp
67.48+2.44+3.75%
HALO
Halozyme Therapeutics Inc
50.71-2.57-4.82%